Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diazepam is a long-acting benzodiazepine used primarily to treat anxiety disorders, alcohol withdrawal symptoms, muscle spasms, spasticity from neurological disorders (such as cerebral palsy and paraplegia), and seizures. It also has applications as a sedative, hypnotic for short-term management of insomnia, premedication before procedures, and in the management of alcohol withdrawal syndrome. Its mechanism of action involves enhancing the effect of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the central nervous system, leading to anxiolytic, anticonvulsant, sedative-hypnotic, muscle relaxant, and amnesic effects[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diazepam.